Pancreatic Ductal Adenocarcinoma is Associated with a Distinct Urinary Metabolomic Signature
- 25 October 2012
- journal article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 20 (S3) , 415-423
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with poor prognosis in part due to the lack of early detection and screening methods. Metabolomics provides a means for noninvasive screening of tumor-associated perturbations in cellular metabolism. Urine samples of PDAC patients (n = 32), healthy age and gender-matched controls (n = 32), and patients with benign pancreatic conditions (n = 25) were examined using 1H-NMR spectroscopy. Targeted profiling of spectra permitted quantification of 66 metabolites. Unsupervised (principal component analysis, PCA) and supervised (orthogonal partial-least squares discriminant analysis, OPLS-DA) multivariate pattern recognition techniques were applied to discriminate between sample spectra using SIMCA-P+ (version 12, Umetrics, Sweden). Clear distinction between PDAC and controls was noted when using OPLS-DA. Significant differences in metabolite concentrations between cancers and controls (p < 0.001) were noted. Model parameters for both goodness of fit, and predictive capability were high (R 2 = 0.85; Q 2 = 0.59, respectively). Internal validation methods were used to confirm model validity. Sensitivity and specificity of the multivariate OPLS-DA model were summarized using a receiver operating characteristics (ROC) curve, with an area under the curve (AUROC) = 0.988, indicating strong predictive power. Preliminary analysis revealed an AUROC = 0.958 for the model of benign pancreatic disease compared with PDAC, and suggest that the cancer-associated metabolomic signature dissipates following RO resection. Urinary metabolomics detected distinct differences in the metabolic profiles of pancreatic cancer compared with healthy controls and benign pancreatic disease. These preliminary results suggest that metabolomic approaches may facilitate discovery of novel pancreatic cancer biomarkers.Keywords
This publication has 43 references indexed in Scilit:
- Urine Metabolic Signature of Pancreatic Ductal Adenocarcinoma by 1H Nuclear Magnetic Resonance: Identification, Mapping, and EvolutionJournal of Proteome Research, 2011
- Metabolomic Profiling of Serum from Human Pancreatic Cancer Patients Using 1H NMR Spectroscopy and Principal Component AnalysisApplied Biochemistry and Biotechnology, 2011
- Feasibility of Identifying Pancreatic Cancer Based on Serum MetabolomicsCancer Epidemiology, Biomarkers & Prevention, 2011
- Pancreatic CancerNew England Journal of Medicine, 2010
- Hereditary pancreatic cancer: A clinical perspectiveBest Practice & Research Clinical Gastroenterology, 2009
- Discrimination of metabolic profiles of pancreatic cancer from chronic pancreatitis by high‐resolution magic angle spinning 1H nuclear magnetic resonance and principal components analysisCancer Science, 2007
- Validation of the 6th edition AJCC pancreatic cancer staging systemCancer, 2007
- Management strategies for patients with hereditary pancreatic cancerCurrent Treatment Options in Oncology, 2005
- Metabolomics: building on a century of biochemistry to guide human healthMetabolomics, 2005
- Measurement of lactate levels in serum and bile using proton nuclear magnetic resonance in patients with hepatobiliary diseases: its utility in detection of malignanciesJapanese Journal of Clinical Oncology, 1997